ODEPHARMA
ActiveSummary
ODEPHARMA has been active since 1990 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €115,621 and a net result of €69,636. Equity has been growing by about 61% per year since 2019. Its solvency ranks better than 59% of 12,777 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 12-09-1990 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 30-09-2023
- Establishment units
- 2.049.732.239 8670 Koksijde, since 08-10-1990
- 2.395.057.088 8670 Koksijde, since 01-10-2026
- Financial year end
- 30 September
- Peppol
- Reachable since 02-10-2025
Board and ownership
Board
- LindammerDirector · since 01-10-2024 · permanent representative Marceau DECRU
Shareholders
- PAN PROJECT99.52%30-09-2023 annual accounts of PAN PROJECT
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.1%
Annual accounts to 30-09-2025
- Gross margin
- €223,178
- ▲ 57.3%
- Turnover
- ≈ €1.0m
- estimated
- Profit
- €69,636
- ▲ 725%
- Equity
- €115,621
- ▲ 151%
- Total assets
- €255,295
- ▲ 12.3%
- Employees on 30-09-2025
- 2
- =
Score breakdownraises riskSector: Retail trade (NACE 47)lowers riskLiquidity: current ratio 1.84, cash €57,952Founded in 1990Equity €115,621 (45.3% of total assets)Show the evidence
Checked score
Score 2025
96
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 76% of micro companies in retail trade (NACE 47)
Financial strength · tick: 2024
Strong
Solvency
70+25
equity 45.3% of total assets
Liquidity
51+35
short-term debt 53.5% · cash 22.7%
Profitability
100+54
return on assets 27.3%
Bankruptcy probability within 12 months
0.1%
Very low
0%0.5%1.5%4%10%≥ 25%
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.8%
01-2025: 0.9%▲ +0.1 percentage points vs 12-2024
02-2025: 1.1%▲ +0.2 percentage points vs 01-2025
03-2025: 1.0%▼ -0.1 percentage points vs 02-2025
04-2025: 1.3%▲ +0.3 percentage points vs 03-2025
05-2025: 1.3%● unchanged vs 04-2025
06-2025: 1.3%● unchanged vs 05-2025
07-2025: 1.3%● unchanged vs 06-2025
08-2025: 1.3%● unchanged vs 07-2025
09-2025: 1.3%● unchanged vs 08-2025
10-2025: 1.3%● unchanged vs 09-2025
11-2025: 1.3%● unchanged vs 10-2025
12-2025: 1.3%● unchanged vs 11-2025
01-2026: 1.5%▲ +0.2 percentage points vs 12-2025
02-2026: 1.8%▲ +0.3 percentage points vs 01-2026highest value
03-2026: 0.3%▼ -1.5 percentage points vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.3%● unchanged vs 05-2026
07-2026: 0.3%● unchanged vs 06-2026
08-2026: 0.3%● unchanged vs 07-2026
09-2026: 0.3%● unchanged vs 08-2026
10-2026: 0.1%▼ -0.2 percentage points vs 09-2026lowest value
11-2026: 0.1%● unchanged vs 10-2026lowest value
Credit of up to €11,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.84 (1.23 in 2024), above the usual 1.5. Short-term debt is 53.5% and cash 22.7% of total assets. However, 54.7% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 60% of them on solvency, 55% on liquidity, 96% on profitability and 95% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 03-02-2026, 86 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
86 days early
2024
34 days early
2023
8 days early
2022
2 days early
2021
2 days early
2020
on the day
2019
8 days early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 20 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 23 April (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-09-2026 year end03-11-2026 today30-04-2027 deadline
Financials
Financials · financial year 2025, abbreviated format
Annual accounts 2025 filed on 03-02-2026 PDF all 35 filings
Turnover
≈ €1.0m
Estimated: probably between €710,000 and €2.0m
Total assets
€255,295▲ 12.3%
2024 · €227,253
Net result
€69,636▲ 725%
2024 · €8,443
Working capital
€114,290▲ 172%
2024 · €42,070
Multi-year overview
2019 to 2025, 7 financial yearsOperating result
€87,084
▲ 693%
2025
20192025
Net result
€69,636
▲ 725%
2025
middle half of the sector
20192025
Equity
€115,621
▲ 151%
2025
middle half of the sector
20192025
Total assets
€255,295
▲ 12.3%
2025
lowest quarter of the sector
20192025
Debt
€139,674
▼ 22.9%
2025
20192025
Working capital
€114,290
▲ 172%
2025
middle half of the sector
20192025
Solvency
45.3%
▲ 25.1pp
2025
middle half of the sector
20192025
Current ratio
1.84
▲ 0.60
2025
middle half of the sector
20192025
Return on assets (ROA)
27.3%
▲ 23.6pp
2025
highest quarter of the sector
20192025
Staff (FTE)
1.9
▲ 5.6%
2025
middle half of the sector
20192025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line2019202020212022202320242025
Operating result€30,825-€13,372▼ 56.6%€39,488▲ 195%€8,800▼ 77.7%€19,757▲ 125%€10,982▼ 44.4%€87,084▲ 693%
Net result€21,533-€16,807within the sector's middle half▼ 21.9%€41,121within the sector's middle half▲ 145%€10,490within the sector's middle half▼ 74.5%€21,444within the sector's middle half▲ 104%€8,443within the sector's middle half▼ 60.6%€69,636within the sector's middle half▲ 725%
Equity-€52,320--€35,513below the sector's middle half▲ 32.1%€5,608below the sector's middle half€16,098below the sector's middle half▲ 187%€37,542below the sector's middle half▲ 133%€45,985below the sector's middle half▲ 22.5%€115,621within the sector's middle half▲ 151%
Total assets€222,829-€205,574below the sector's middle half▼ 7.7%€222,758below the sector's middle half▲ 8.4%€199,436below the sector's middle half▼ 10.5%€214,842below the sector's middle half▲ 7.7%€227,253below the sector's middle half▲ 5.8%€255,295below the sector's middle half▲ 12.3%
Debt€275,149-€241,087▼ 12.4%€217,151▼ 9.9%€183,338▼ 15.6%€177,300▼ 3.3%€181,268▲ 2.2%€139,674▼ 22.9%
Working capital€16,977-€24,767within the sector's middle half▲ 45.9%€138,574within the sector's middle half▲ 460%€98,020within the sector's middle half▼ 29.3%€120,515within the sector's middle half▲ 22.9%€42,070within the sector's middle half▼ 65.1%€114,290within the sector's middle half▲ 172%
Solvency-23.5%--17.3%below the sector's middle half▲ 6.2pp2.5%below the sector's middle half▲ 19.8pp8.1%below the sector's middle half▲ 5.6pp17.5%below the sector's middle half▲ 9.4pp20.2%within the sector's middle half▲ 2.8pp45.3%within the sector's middle half▲ 25.1pp
Current ratio1.09-1.14within the sector's middle half▲ 0.062.81above the sector's middle half▲ 1.672.04within the sector's middle half▼ 0.772.37within the sector's middle half▲ 0.331.23within the sector's middle half▼ 1.131.84within the sector's middle half▲ 0.60
Return on assets (ROA)9.7%-8.2%within the sector's middle half▼ 1.5pp18.5%above the sector's middle half▲ 10.3pp5.3%within the sector's middle half▼ 13.2pp10.0%within the sector's middle half▲ 4.7pp3.7%within the sector's middle half▼ 6.3pp27.3%above the sector's middle half▲ 23.6pp
Staff (FTE)2-1.9within the sector's middle half▼ 5.0%1.8within the sector's middle half▼ 5.3%1.8within the sector's middle half=1.8within the sector's middle half=1.8within the sector's middle half=1.9within the sector's middle half▲ 5.6%
above
within
below
The sector band is the middle half of the companies in Retail trade (NACE 47). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 7.9 times that of 2024 and the highest since 2021. It is a recovery after the fall in 2024.
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €255,295
Fixed assets
€4,412 ▼ 19.1%
Current assets
€250,882 ▲ 13.1%
Equity and liabilities €255,295
Equity
€115,621 ▲ 151%
Debt
€139,674 ▼ 22.9%
Debt's share of the balance-sheet total falls from 79.8% to 54.7%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€88,126▲
2024 · €11,973
Cash flow
€70,678▲
2024 · €9,434
Quick ratio
0.91▲
2024 · 0.54
Debt to equity
1.21▼
2024 · 3.94
ROE
60.2%▲
2024 · 18.4%
Interest coverage
85.53▲
2024 · 2.72
Debt ≤ 1 year
€136,592▼
2024 · €179,728
Income taxes
€18,004▲
2024 · €2
Staff costs
€134,044▲
2024 · €128,920
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Staff
| Item | 30-09-2021 | 30-09-2022 | 30-09-2023 | 30-09-2024 | 30-09-2025 |
|---|---|---|---|---|---|
| Employees at the balance-sheet date | 2 | 2 | 2 | 2 | 2 |
| full-time | 1 | 1 | 1 | 1 | 1 |
| part-time | 1 | 1 | 1 | 1 | 1 |
| in full-time equivalents | 1.8 | 1.8 | 1.8 | 1.8 | 1.9 |
| Average over the year, in full-time equivalents | 1.8 | 1.8 | 1.8 | 1.8 | 1.9 |
| On a permanent contract | 2 | 2 | 2 | 2 | 2 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Investments
| Item | 30-09-2021 | 30-09-2022 | 30-09-2023 | 30-09-2024 | 30-09-2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €759 | €1,849 | - | €1,394 | - |
| Depreciation and write-downs of the year | €2,118 | €2,489 | €974 | €991 | €1,042 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Annual accounts
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | - | €99,085 | €112,005 | €124,450 | €128,920 | €134,044 | ▲ 4.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €3,014 | €2,220 | €2,118 | €2,489 | €974 | €991 | €1,042 | ▲ 5.2% |
| Other operating charges640/8 | - | - | €2,056 | €1,910 | €2,341 | €923 | €1,008 | ▲ 9.2% |
| Non-recurring operating charges66A | - | - | - | - | - | €100 | €0 | ▼ 100% |
| Gross operating margin9900 | €138,466 | €122,478 | €142,746 | €125,204 | €147,523 | €141,917 | €223,178 | ▲ 57.3% |
| Operating profit (loss)9901 | €30,825 | €13,372 | €39,488 | €8,800 | €19,757 | €10,982 | €87,084 | ▲ 693% |
| Financial income75/76B | - | - | €2,226 | €2,237 | €2,018 | €1,866 | €1,586 | ▼ 15.0% |
| Recurring financial income75 | €2,111 | €3,677 | €2,226 | €2,237 | €2,018 | €1,866 | €1,586 | ▼ 15.0% |
| Financial charges65/66B | - | - | €593 | €547 | €332 | €4,403 | €1,030 | ▼ 76.6% |
| Recurring financial charges65 | €11,403 | €241 | €593 | €547 | €332 | €4,403 | €1,030 | ▼ 76.6% |
| Profit (loss) for the period before taxes9903 | €21,533 | €16,807 | €41,121 | €10,490 | €21,444 | €8,445 | €87,639 | ▲ 938% |
| Income taxes67/77 | €0 | - | - | - | - | €2 | €18,004 | ▲ 8,183× |
| Profit (loss) for the period9904 | €21,533 | €16,807 | €41,121 | €10,490 | €21,444 | €8,443 | €69,636 | ▲ 725% |
| Profit (loss) for the period to be appropriated9905 | €21,533 | €16,807 | €41,121 | €10,490 | €21,444 | €8,443 | €69,636 | ▲ 725% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €222,829 | €205,574 | €222,758 | €199,436 | €214,842 | €227,253 | €255,295 | ▲ 12.3% |
| Fixed assets21/28 | €8,421 | €9,108 | €7,749 | €7,109 | €6,135 | €5,455 | €4,412 | ▼ 19.1% |
| Tangible fixed assets22/27 | €4,870 | €5,556 | €4,197 | €3,558 | €2,583 | €2,986 | €1,944 | ▼ 34.9% |
| Plant, machinery and equipment23 | - | - | €1,534 | €1,500 | €1,130 | €760 | €390 | ▼ 48.7% |
| Furniture and vehicles24 | - | - | €794 | €397 | €0 | €980 | €516 | ▼ 47.4% |
| Other tangible fixed assets26 | - | - | €1,869 | €1,661 | €1,454 | €1,246 | €1,038 | ▼ 16.7% |
| Financial fixed assets28 | €3,551 | €3,551 | €3,551 | €3,551 | €3,551 | €2,469 | €2,469 | = |
| Current assets29/58 | €214,408 | €196,466 | €215,010 | €192,327 | €208,707 | €221,798 | €250,882 | ▲ 13.1% |
| Stocks and contracts in progress3 | €117,341 | €106,582 | €110,394 | €111,823 | €119,560 | €125,517 | €126,241 | ▲ 0.6% |
| Stocks30/36 | - | - | €110,394 | €111,823 | €119,560 | €125,517 | €126,241 | ▲ 0.6% |
| Amounts receivable within one year40/41 | €62,831 | €66,709 | €53,995 | €59,591 | €58,004 | €69,277 | €63,718 | ▼ 8.0% |
| Trade receivables40 | - | - | €34,080 | €53,712 | €49,570 | €57,954 | €63,485 | ▲ 9.5% |
| Other amounts receivable41 | - | - | €19,916 | €5,879 | €8,434 | €11,323 | €233 | ▼ 97.9% |
| Cash at bank and in hand54/58 | €31,055 | €15,755 | €43,944 | €13,117 | €23,032 | €15,844 | €57,952 | ▲ 266% |
| Deferred charges and accrued income490/1 | - | - | €6,677 | €7,797 | €8,111 | €11,160 | €2,972 | ▼ 73.4% |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €222,829 | €205,574 | €222,758 | €199,436 | €214,842 | €227,253 | €255,295 | ▲ 12.3% |
| Equity10/15 | -€52,320 | -€35,513 | €5,608 | €16,098 | €37,542 | €45,985 | €115,621 | ▲ 151% |
| Contributions10/11 | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | = |
| Capital10 | - | - | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | = |
| Issued capital100 | - | - | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | = |
| Reserves13 | €6,500 | €6,500 | €6,500 | €6,500 | €6,500 | €6,500 | €53,500 | ▲ 723% |
| Non-distributable reserves130/1 | - | - | €6,500 | €6,500 | €6,500 | €6,500 | €6,500 | = |
| Legal reserve130 | - | - | €6,500 | €6,500 | €6,500 | €6,500 | €6,500 | = |
| Distributable reserves133 | - | - | - | - | - | - | €47,000 | - |
| Profit (loss) carried forward14 | -€120,820 | -€104,013 | -€62,892 | -€52,402 | -€30,958 | -€22,515 | €121 | - |
| Amounts payable17/49 | €275,149 | €241,087 | €217,151 | €183,338 | €177,300 | €181,268 | €139,674 | ▼ 22.9% |
| Amounts payable after more than one year17 | €76,870 | €68,830 | €140,284 | €88,494 | €88,494 | €0 | - | - |
| Financial debts170/4 | - | - | €8,040 | €0 | - | - | - | - |
| Other amounts payable178/9 | - | - | €132,244 | €88,494 | €88,494 | €0 | - | - |
| Amounts payable within one year42/48 | €197,431 | €171,699 | €76,435 | €94,307 | €88,193 | €179,728 | €136,592 | ▼ 24.0% |
| Current portion of amounts payable after more than one year42 | - | - | €8,040 | €8,040 | €0 | €88,494 | €0 | ▼ 100% |
| Trade debts44 | €68,551 | €73,282 | €42,525 | €55,694 | €56,279 | €68,052 | €41,914 | ▼ 38.4% |
| Suppliers440/4 | - | - | €42,525 | €55,694 | €56,279 | €68,052 | €41,914 | ▼ 38.4% |
| Taxes, remuneration and social security45 | - | - | €16,524 | €15,064 | €18,384 | €16,946 | €26,277 | ▲ 55.1% |
| Taxes450/3 | - | - | €2,721 | €0 | €1,772 | €0 | €4,007 | - |
| Remuneration and social security454/9 | - | - | €13,803 | €15,064 | €16,612 | €16,946 | €22,270 | ▲ 31.4% |
| Other amounts payable47/48 | - | - | €9,346 | €15,509 | €13,530 | €6,235 | €68,401 | ▲ 997% |
| Accrued charges and deferred income492/3 | - | - | €431 | €537 | €613 | €1,540 | €3,081 | ▲ 100% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €21,533 | €16,807 | €41,121 | €10,490 | €21,444 | €8,443 | €69,636 | ▲ 725% |
| + Depreciation and write-downs630 | €3,014 | €2,220 | €2,118 | €2,489 | €974 | €991 | €1,042 | ▲ 5.2% |
| Operating cash flow (approximation) | €24,547 | €19,027 | €43,238 | €12,979 | €22,418 | €9,434 | €70,678 | ▲ 649% |
| Investment in fixed assets (approximation) | - | -€2,907 | -€759 | -€1,849 | €0 | -€311 | €0 | - |
| Change in cash | - | -€15,300 | €28,189 | -€30,827 | €9,916 | -€7,188 | €42,108 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 31,368 companies had the same profile as ODEPHARMA has now. Two years later, 93.5% were still going and 0.5% had gone bankrupt.
- Micro
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
93.5%
was still going
5.9%
stopped otherwise
0.5%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of ODEPHARMA itself: 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 31,368 companies, not a prediction for ODEPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 35 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-09-2025 | abbreviated format | 03-02-2026 | 2026-00034850 | |
| 30-09-2024 | abbreviated format | 27-03-2025 | 2025-00055972 | |
| 30-09-2023 | abbreviated format | 22-04-2024 | 2024-00066009 | |
| 30-09-2022 | abbreviated format | 28-04-2023 | 2023-00070753 | |
| 30-09-2021 | abbreviated format | 28-04-2022 | 2022-20010751 | |
| 30-09-2020 | abbreviated format | 30-04-2021 | 2021-12000590 | |
| 30-09-2019 | abbreviated format | 22-04-2020 | 2020-09400588 | |
| 30-09-2018 | abbreviated format | 30-04-2019 | 2019-11300001 | |
| 30-09-2017 | abbreviated format | 10-04-2018 | 2018-09400189 | |
| 30-09-2016 | abbreviated format | 07-04-2017 | 2017-09000238 |
Board & ownership
Directors
Directors
1 director, last change in 2024
Board 1
Lindammer
Current
Director (not named in the articles) · since 01-10-2024 · 6-year term from 2024 · Limited partnership · permanent representative: Marceau DECRU · also on the board of 3 other companies · listed in the 2025 annual accounts, filed on 03-02-2026
Permanent representatives 1
Marceau DECRU
Current
Permanent representative · appointed in the act of 22-10-2024 · for Lindammer
Signing authorityThe articles say who may bind the company, for example by signing a contract.
The sole director
deed of 27-12-2024Owners and capital
Shareholders
1 ownerChain of control
- PAN PROJECT
- ODEPHARMA
Owners 1
- PAN PROJECTparentEquity €64,999 Profit of €227,940 in 2024 (loss of €4,414 in 2023)99.52%
Capital transactions
Capital over time
- 27-12-2024 Capital stated in the deed · €62,000 · 1,250 shares
Mandate history
4 people, 1 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Lindammer |
|
| An LOUWAGIE |
|
| Kristiaan TRYPSTEEN |
|
| PAN PROJECT |
|
Articles of association
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- “Bestuurder, 1”
Articles of association, deed of 27-12-2024 (in Dutch)
Network & group
Connections & network
3 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
ALMAPHARMA
Shared corporate director
→
Apotheek Albert I
Shared corporate director
→
APOTHEEK SINT-IDESBALD
Shared corporate director
→
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
03-02
abbreviated format · 86 days before the deadline
2025
30-09
Financial
Highest result from 2019 to 2025net €69,636 ▲725%
The operating result of €87,084 and the net result of €69,636 are both a record.
30-09
Financial
Equity above €100,000equity €115,621 ▲151%
With a profit in every financial year since 2019, equity grows to €115,621.
27-03
abbreviated format · 34 days before the deadline
2024
27-12
Gazette deed
Company renamed from APOTHEEK STAELENS - MOEYAERT to ODEPHARMAAmendment of the articles · Capital · Power of attorney5 points ▸
Gazette deed
Company renamed from APOTHEEK STAELENS - MOEYAERT to ODEPHARMA
Amendment of the articles · Capital · Power of attorney5 points ▸
- General meeting, “eenparigheid van de stemmen”, 19-12-2024 (deed in Dutch)
- Amendment of the articles, mentioned 2 times in the deed
- Name change, ODEPHARMA
- Capital, €62,000
- Power of attorney
22-10
Gazette deed
Registered office moved from De Panne to OostduinkerkeNew seat: 8670 Oostduinkerke, Leopold II Laan 168 · Previous seat: Zeelaan 135, 8660 De Panne · Resignations: An LOUWAGIE, Kristiaan TRYPSTEEN and PAN PROJECT CV10 points ▸
Gazette deed
Registered office moved from De Panne to Oostduinkerke
New seat: 8670 Oostduinkerke, Leopold II Laan 168 · Previous seat: Zeelaan 135, 8660 De Panne · Resignations: An LOUWAGIE, Kristiaan TRYPSTEEN and PAN PROJECT CV10 points ▸
- General meeting, 01-10-2024
- Director resignation, An LOUWAGIE (director (not named in the articles))
- Director resignation, Kristiaan TRYPSTEEN (director (not named in the articles))
- Director resignation, PAN PROJECT CV (director (not named in the articles))
- Permanent representative, Philip HERMAN
- Director appointment, LINDAMMER CommV (director (not named in the articles))
- Permanent representative, Marceau DECRU
- Board meeting, 01-10-2024
- Director resignation, Kristiaan TRYPSTEEN (day-to-day manager)
- Registered-office move, 8670 Oostduinkerke, Leopold II Laan 168
30-09
Financial
Weakest financial yearnet €8,443 ▼60.6%
The net result drops to €8,443, the lowest from 2019 to 2025. It recovers the following year.
10-05
Gazette deed
4 reappointedReappointments: An Louwagie, Kristiaan Trypsteen and CV PAN PROJECT · Permanent representative: Philip Herman7 points ▸
Gazette deed
4 reappointed
Reappointments: An Louwagie, Kristiaan Trypsteen and CV PAN PROJECT · Permanent representative: Philip Herman7 points ▸
- General meeting, 23-02-2023
- Director reappointment, An Louwagie (director)
- Director reappointment, Kristiaan Trypsteen (director)
- Director reappointment, CV PAN PROJECT (director)
- Permanent representative, Philip Herman
- Board meeting, 23-02-2023
- Director reappointment, Kristiaan Trypsteen (managing director)
22-04
abbreviated format · 8 days before the deadline
2023
28-04
abbreviated format · 2 days before the deadline
2022
28-04
abbreviated format · 2 days before the deadline
2021
30-09
Financial
Liquidity more than doubledcurrent ratio 2.81
The current ratio rises from 1.14 to 2.81. Short-term debt falls from €171,699 to €76,435.
Show earlier events
30-04
abbreviated format · on the deadline day
2020
22-04
abbreviated format · 8 days before the deadline
2019
30-04
abbreviated format · on the deadline day
2018
10-04
abbreviated format · 20 days before the deadline
2017
07-04
abbreviated format · 23 days before the deadline
1990
06-10
Gazette deed
Incorporation
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
ODEPHARMA in Dutch
Former name
APOTHEEK STAELENS - MOEYAERT until the act of 27-12-2024
Enterprise number
0441.639.812
Legal form
Public limited company
Status
Active, normale toestand
Founded
12-09-1990
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 27-12-2024 (in Dutch)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest, bij enkel besluit van het bestuursorgaan, administratieve zetels, agentschappen, werkhuizen, stapelplaatsen en bijkantoren…”
deed of 27-12-2024 (in Dutch)Registered office and establishments
Registered office
Leopold II Laan(Odk) 168, 8670 Koksijde, Belgium
Establishment units
APOTHEEK PHARMACIE, Leopold II Laan(Odk) 168, 8670 Koksijde since 08-10-1990 · unit number 2.049.732.239
APOTHEEK PHARMACIE, Leopold II Laan(Odk) 57, 8670 Koksijde since 01-10-2026 · unit number 2.395.057.088
Activities
NACEBEL 2025VAT activities
47730
Retail sale of pharmaceutical products main activity
Social security (RSZ) activities
47730
Retail sale of pharmaceutical products main activity
Codes under NACEBEL 2008
VAT activities
47730
Retail trade main activity
Social security (RSZ) activities
47730
Retail trade main activity
Codes under NACEBEL 2003
52310
main activity
Joint committee
313 Paritair Comité voor de apotheken en tarificatiediensten annual accounts 30-09-2023
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 27-12-2024 (in Dutch)
“Het oprichten, overnemen, overlaten en uitbaten van apotheken, aankoop en verkoop, in- en uitvoer, fabricatie in het groot en in het klein…”
9 activities
- Het oprichten, overnemen, overlaten en uitbaten van apotheken, aankoop en verkoop, in- en uitvoer, fabricatie in het groot en in het klein van scheikundige, pharmaceutische en para-pharmaceutische artikelen
- De handel en groothandel in drogisterij-parfumerie, schoonheids-, toilet-, verband-, dieet-, laboratorium-, optische en onderhoudsartikelen en aanverwante produkten en diensten
- De aankoop, verkoop en bereiding, in het groot of in het klein, van dermatologische produkten en preparaten
- De aankoop, verkoop en bereiding in het groot of in het klein van homeopathische produkten en kruiden
- De aankoop, verkoop en bereiding in het groot of in het klein van veeartsenijprodukten
- Het ondernemen van industriële en klinische ontledingen
- Het uitbaten van thuiszorgwinkels
- Iedere handelsbedrijvigheid welke met de gezondheidszorg verband houdt, in de ruimste zin genomen
- Het verlenen van allerhande dienstverlenende functies aan apothekers, fabrikanten en leveranciers van geneesmiddelen, pharmaceutische, dermatologische en homeopathische producten, zoals het verlenen van advies, het uitvoeren van studies, het uitvoeren van administratieve taken enz…
Invoicing and payment
VAT number
BE 0441.639.812
Financial year and general meeting
Accounts at the NBBFinancial year end
30-09
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Last Thursday of February at 14:00
deed of 27-12-2024 (in Dutch)Recognitions · licences · registrations
Food safety, FASFC
2 sitesKoksijdeunit number 2.049.732.239
Koksijdeunit number 2.395.057.088
Sites & property
Location
Buildings and parcels at the addresses
Ground area
701 m²
Building footprint
318 m²
Building volume
2,581 m³
Tallest building: 13.1 m.
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 38502E0097/00D000 | Flanders | 426 m² | 1 · 212 m² | 12.1 m · 3 |
| 38502G0515/00_000 | Flanders | 275 m² | 1 · 106 m² | 13.1 m · 3 |